Ketamine for Pain, Acute

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Summa Health System, Akron, OH
Pain, Acute+4 More
Ketamine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This will be an intent to treat prospective, double blind, double-dummy, randomized trial. Our primary objective is the reduction of side effects of sub dissociative dose ketamine given by slow intravenous (IV) infusion over 30 minutes vs. 15 minutes in the treatment of acute, severe pain in Emergency Department (ED) patients. The secondary objective will be to maintain adequate pain control (as defined by a Visual Analog Scale (VAS) score of ≤ 5cm) at 30 minutes for both groups.

Eligible Conditions

  • Pain, Acute
  • Dissociation

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Pain, Acute

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 30 minutes

30 minutes
Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) Score
Visual Analog Scale (VAS) Score

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Pain, Acute

Trial Design

2 Treatment Groups

Ketamine 15 Minutes
1 of 2
Ketamine 30 Minutes
1 of 2
Active Control
Experimental Treatment

48 Total Participants · 2 Treatment Groups

Primary Treatment: Ketamine · No Placebo Group · Phase 4

Ketamine 30 Minutes
Drug
Experimental Group · 1 Intervention: Ketamine · Intervention Types: Drug
Ketamine 15 Minutes
Drug
ActiveComparator Group · 1 Intervention: Ketamine · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1160

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 minutes
Closest Location: Summa Health System · Akron, OH
2007First Recorded Clinical Trial
1 TrialsResearching Pain, Acute
49 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Pain described as abdominal, flank, back, musculoskeletal, or traumatic chest pain.
You are able to give informed consent.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.